Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Pharmacy Zocor Faces “Major Challenges” Communicating Risk Factors

This article was originally published in The Tan Sheet

Executive Summary

Communicating appropriate cardiac risk factors for self-selection of statins still presents an obstacle for Zocor Heart-Pro (simvastatin 10 mg) despite the drug's pharmacy status, according to McNeil Europe VP-R&D Stephen Mann, MD

You may also be interested in...



Mevacor OTC Panel Rejection Elicits Third Drug Class Talk

A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists

Non-Rx Zocor Will Be Available In UK Without Cholesterol Screen Requirement

Customers who present at UK pharmacies to purchase McNeil Europe's Zocor Heart-Pro (simvastatin 10 mg) without a prescription will need to disclose risk factors such as age and family history of heart disease, but not necessarily their cholesterol level, under a marketing plan cleared by the UK health agency

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel